capecitabine
PrintTrade Name(s): Xeloda; Capecitabine | |
Group 1: Antineoplastic Hazardous | AHFS Class: Antineoplastic Agents |
Activity | Gloves | Gown | Eye/Face | Mask | Notes/Instructions |
Dispensing prepackaged formulations |
| ||||
Counting/Repackaging tablets or capsules | Recommended if pregnant, breast feeding, or trying to conceive. | If risk of dust inhalation |
| ||
Repackaging oral liquids | If risk of spill or splash | If risk of inhalation |
|
Formulation | Gloves | Gown | Eye/Face | Mask | Notes/Instructions |
Tablet or capsule - from unit-dose package | or Recommended if pregnant, breast feeding, or trying to conceive. |
| |||
Liquid - oral or feeding tube | If potential for splash, vomit or spit up |
|
Reference: NIOSH 2016, USP <800>
Type of Instance | Gloves | Gown | Mask | Eye/Face | Notes/Instructions |
Receiving undamaged HD shipping container |
| ||||
Receiving damaged HD shipping container | If container must be opened | If container must be opened | If container must be opened |
| |
Spill Cleanup | Large volume | Large volume |
|
Reference: USP <800>
Hazardous Pharmaceutical | Trace Chemo | Biohazardous and Sharps |
1. Non-returnable hazardous, chemo and EPA regulated drugs. (Patient specific prescriptions, partially used blister packs, containers with more than 3% medication remaining) 2. Empty bottles or packaging of P-Listed drugs. (Warfarin, nicotine, epinephrine, nitroglycerin, physostigmine) 3. PPE with visible contamination from hazardous drug. | 1. Waste contaminated through contact with chemotherapeutic agents. (Empty vials, IV bags, syringes and tubing) 2. PPE worn while handling hazardous drugs with NO visible contamination. (Gowns, gloves and masks) 3. Used CSTD devices. | 1. All sharps capable of cutting or piercing the skin. (Needles/syringes, broken ampules, lancets) 2. Items contaminated with blood or other potentially infectious materials. (Tubing, bags or dressings containing blood, contaminated waste from isolation patients) |
Dosage Form | Ship to Institution or Pharmacy | Ship to Locations Outside of ODOC |
Tablets and Capsules |
|
|
Liquid, Topical, and Transdermal |
|
|
PPE | Standards |
Shoe Covers |
|
Gowns |
|
Gloves |
|
Face Shields |
|
Goggles |
|
N95 Masks |
|
Removal and Disposal |
|
Reference: USP <800>
- Suspected of causing genetic defects.
- May cause cancer.
- May damage fertility or the unborn child.
- Wear {protective gloves/protective clothing/eye protection/face protection}.
Reference: SDS - Cayman Chemical
Capecitabine is a prodrug that is selectively tumour-activated to its cytotoxic moiety, fluorouracil, by thymidine phosphorylase, an enzyme found in higher concentrations in many tumors compared to normal tissues or plasma. Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP), within normal and tumour cells. These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deaxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, therefore a deficiency of this compound can inhibit cell division. Secondly, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis through the production of fraudulent RNA.
Reference: Drug Bank